A systematic review reveals benefits of monoclonal antibodies in relapsing remitting multiple sclerosis, suggesting targeted use for better outcomes.
Monoclonal antibodies are an effective option in RRMS, with clinical and radiological benefits superior to those of conventional treatments. Their use requires individualized assessment and close follow-up due to the risk of adverse effects, especially in high-risk patients.
No takes yet. Share an insight, caveat, or question.
Avedillo-Salas et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: